Comments
US based Cephalon Inc has sued Glenmark Pharmaceuticals and its US-based subsidiary Glenmark Generics over patent breach on a leukaemia drug.
The Mumbai-headquartered company and its US subsidiary confirmed that Cephalon had filed the patent infringement suit on December 26 in the US District Court for the District of Delaware.
Cephalon is an indirect wholly owned subsidiary of generic major Teva Pharmaceutical.
Glenmark has been slapped with a patent infringement case by Cephalon over its plans to sell a generic version of a leukaemia treatment drug Treanda in the US market.
The patent infringement suit sought to prevent Glenmark from commercialising its Abbreviated New Drug Application (ANDA) for Bendamustine Hydrochloride product, its generic version of Treanda.
Bendamustine is indicated for the treatment of patients with chronic lymphocytic leukemia. The ANDA has been filed from Glenmark's Argentina facility.
For the 12-month period ended September 30, 2013, Treanda achieved sales of $669 million, according to IMS Health data.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.